AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

January 3, 2020 GMT

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Jan 3, 2020--

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 8:00 a.m. PST in San Francisco.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.

About Glaukos

Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200103005028/en/

CONTACT: Chris Lewis

Director, Investor Relations, Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH MEDICAL DEVICES SURGERY FINANCE PHARMACEUTICAL OPTICAL

SOURCE: Glaukos Corporation

Copyright Business Wire 2020.

PUB: 01/03/2020 07:15 AM/DISC: 01/03/2020 07:15 AM

http://www.businesswire.com/news/home/20200103005028/en